Veru announces presentation of phase 2 study of enobosarm -- a selective androgen receptor targeting agent in metastatic ar+er+her2- breast cancer at 2021 esmo breast cancer congress

Miami, april 21, 2021 (globe newswire) -- veru inc. (nasdaq: veru), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that clinical results from the phase 2 clinical study of enobosarm, a selective androgen receptor targeting agonist, in heavily pretreated women with ar+er+her2- advanced breast cancer including further efficacy data and an analysis of patients who have failed both estrogen blocking agents and cdk 4/6 inhibitors, has been accepted for a poster presentation at the european society for medical oncology (esmo) breast cancer virtual congress 2021 to be held may 05-08, 2021. enobosarm is an oral, first-in-class, selective androgen receptor targeting agonist that activates the androgen receptor, a tumor suppressor, in ar+er+her2- metastatic breast cancer. the planned phase 3 artest study will evaluate enobosarm monotherapy versus an active control (exemestane or serm) for the treatment of metastatic ar+er+her2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor (anastrozole or letrozole), fulvestrant, and a cdk 4/6 inhibitor and the study is anticipated to commence in q2 2021.
VERU Ratings Summary
VERU Quant Ranking